What Can We Expect For Intuitive’s Q2’16 Earnings?

Intuitive Surgical  (NYSE:ISRG) is set to report its Q2 2016 earnings on July 19th. Despite the Brexit, the company’s stock price hit an all time high this month, as investors took note of the company’s strong growth prospects. In the past few quarters, the company has been consistently beating analyst estimates. This can be attributed to the strong growth witnessed by the company for its daVinci systems.  This growth is driven by: 1) the strong adoption of daVinci Xi Systems in the U.S.; 2) growth in the use of daVinci Systems outside the U.S.; and, 3) the increased adoption of daVinci Systems in general surgeries beyond its standard usage in cardiac and gynecologic surgical applications. Further, in Q1’16 the company received FDA clearances in the U.S. for single-site instruments and the 30mm EndoWrist stapler products for the da Vinci XiSurgical System. This can provide incremental revenues going forward.

We believe that robotic surgery is in its infancy and there remains ample growth opportunity for Intuitive going ahead, as it expands the range of procedures offered through the daVinci systems and grows its reach to other regions internationally. From the table below we can observe that analysts are confident that the company has likely seen strong growth in Q2’16.

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology